Amneal announces u.s. fda filing acceptance of abbreviated new drug application for naloxone hydrochloride nasal spray, usp, 4mg

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) today announced the u.s. food and drug administration (fda) has accepted for review the abbreviated new drug application (anda) for naloxone hydrochloride nasal spray, usp, 4mg, which is the generic version of narcan® and is used in the treatment of a known or suspected opioid overdose emergency.
AMRX Ratings Summary
AMRX Quant Ranking